pteridines has been researched along with Medulloblastoma in 5 studies
Medulloblastoma: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We here assessed the therapeutic efficacy of the orally bioavailable BRD4 inhibitor, MK-8628, in preclinical models of medulloblastoma." | 5.51 | Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. ( Althoff, K; Bei, Y; Deubzer, HE; Eggert, A; Garcia, HD; Han, Y; Henssen, AG; Künkele, A; Lindner, S; Lissat, A; Odersky, A; Schramm, A; Schulte, JH; Timme, N, 2019) |
| "These findings support the further exploration of volasertib for pediatric malignancies, particularly alveolar rhabdomyosarcoma, and its combination with mitotic spindle poison." | 3.83 | Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. ( Abbou, S; Daudigeos-Dubus, E; Geoerger, B; Lanvers-Kaminsky, C; Laplace-Builhe, C; LE Dret, L; Molenaar, J; Vassal, G, 2016) |
| " We here assessed the therapeutic efficacy of the orally bioavailable BRD4 inhibitor, MK-8628, in preclinical models of medulloblastoma." | 1.51 | Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. ( Althoff, K; Bei, Y; Deubzer, HE; Eggert, A; Garcia, HD; Han, Y; Henssen, AG; Künkele, A; Lindner, S; Lissat, A; Odersky, A; Schramm, A; Schulte, JH; Timme, N, 2019) |
| "Medulloblastoma is the most common malignant brain tumor in children." | 1.39 | Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. ( Berns, R; Bouffet, E; Dunham, C; Dunn, SE; Foster, C; Fotovati, A; Hawkins, C; Hukin, J; Lee, C; Manoranjan, B; Narendran, A; Northcott, P; O'Halloran, K; Pambid, MR; Ramaswamy, V; Rassekh, R; Singh, SK; Singhal, A; Taylor, MD; Triscott, J; Venugopal, C; Yip, S, 2013) |
| "Medulloblastoma is the most common malignant brain tumor in children and remains a therapeutic challenge due to its significant therapy-related morbidity." | 1.38 | Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. ( Alimova, I; Birks, DK; Donson, AM; Dubuc, A; Foreman, NK; Handler, MH; Harris, PS; Knipstein, J; Taylor, MD; Venkataraman, S; Vibhakar, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, Y | 1 |
| Lindner, S | 1 |
| Bei, Y | 1 |
| Garcia, HD | 1 |
| Timme, N | 1 |
| Althoff, K | 1 |
| Odersky, A | 1 |
| Schramm, A | 1 |
| Lissat, A | 1 |
| Künkele, A | 1 |
| Deubzer, HE | 1 |
| Eggert, A | 1 |
| Schulte, JH | 1 |
| Henssen, AG | 1 |
| Pambid, MR | 2 |
| Berns, R | 2 |
| Adomat, HH | 1 |
| Hu, K | 1 |
| Triscott, J | 2 |
| Maurer, N | 1 |
| Zisman, N | 1 |
| Ramaswamy, V | 2 |
| Hawkins, CE | 1 |
| Taylor, MD | 3 |
| Dunham, C | 2 |
| Guns, E | 1 |
| Dunn, SE | 2 |
| Lee, C | 1 |
| Foster, C | 1 |
| Manoranjan, B | 1 |
| Fotovati, A | 1 |
| Venugopal, C | 1 |
| O'Halloran, K | 1 |
| Narendran, A | 1 |
| Hawkins, C | 1 |
| Bouffet, E | 1 |
| Singhal, A | 1 |
| Hukin, J | 1 |
| Rassekh, R | 1 |
| Yip, S | 1 |
| Northcott, P | 1 |
| Singh, SK | 1 |
| Abbou, S | 1 |
| Lanvers-Kaminsky, C | 1 |
| Daudigeos-Dubus, E | 1 |
| LE Dret, L | 1 |
| Laplace-Builhe, C | 1 |
| Molenaar, J | 1 |
| Vassal, G | 1 |
| Geoerger, B | 1 |
| Harris, PS | 1 |
| Venkataraman, S | 1 |
| Alimova, I | 1 |
| Birks, DK | 1 |
| Donson, AM | 1 |
| Knipstein, J | 1 |
| Dubuc, A | 1 |
| Handler, MH | 1 |
| Foreman, NK | 1 |
| Vibhakar, R | 1 |
5 other studies available for pteridines and Medulloblastoma
| Article | Year |
|---|---|
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Topics: Acetanilides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dr | 2019 |
Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cerebellar Neoplasms; Child; Chromatogr | 2014 |
Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Topics: Adolescent; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Cycle Proteins; Child; Child, Pres | 2013 |
Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Neoplasm | 2016 |
Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
Topics: Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cerebellar | 2012 |